ClinicalTrials.gg
CompletedNCT03619213DELIVERUpdated Jul 11, 2023Results posted

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

A Phase 3 interventional study of Dapagliflozin and Placebo in Heart Failure With Preserved Ejection Fraction, sponsored by AstraZeneca. Completed at 348 sites in 20 countries. Open to participants aged 40 Years to 130 Years. Per ClinicalTrials.gov, last updated 2023-07-11.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6,263
Allocation
Randomized
Ages
40 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing dapagliflozin in Heart Failure — 15 open to participants now, 19 under way, 6 of them phase 3. dapagliflozin · Heart Failure.

Enrollment
3rd of 59
6,263 · median 100
Started
2018
the only one that year
Phase 3
16 of 59
5 open now
Registered
5th of 59
by date
Lead sponsor
7 of 59
AstraZeneca

Among the 59 studies testing dapagliflozin in Heart Failure, this one is the 3rd largest by enrollment, is the only one that started in 2018, is one of 16 in phase 3, and was the 5th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

15 of the 59 studies testing dapagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 40 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing dapagliflozin in Heart Failure, or all of them as a file.
02

Study summary

This is an international, multicentre, parallel-group, event-driven, randomised, double-blind, placebo-controlled study in HFpEF patients, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments to control co-morbidities, in reducing the composite of CV death or heart failure events.

Read the detailed description

This is an international, multicentre, parallel-group, event-driven, randomised, double-blind study in patients with HFpEF, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments to control co-morbidities, in reducing the composite of CV death and heart failure events (hospitalisations for HF or urgent HF visits). Adult patients aged ≥40 years with HFpEF (LVEF >40% and evidence of structural heart disease) and New York Heart Association (NYHA) class II-IV who are eligible according to the inclusion/exclusion criteria will be randomised in a 1:1 ratio to receive either dapagliflozin 10 mg or placebo. Both out-patients and in-patients hospitalised for heart failure and off intravenous heart failure-therapy for 24 hours can be randomised. It is estimated that approximately 11000 patients at approximately 400-500 sites in 20-25 countries will need to be enrolled to reach the target of approximately 6100 randomised patients.

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction

Browse trials for

04

Who can participate

Ages eligible
40 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed prior to any study specific procedures.
  2. Male or female patients age ≥40 years.
  3. Documented diagnosis of symptomatic heart failure ( class II-IV) at enrolment, and a medical history of typical symptoms/signs of heart failure ≥6 weeks before enrolment with at least intermittent need for diuretic treatment.
  4. (LVEF) >40% and evidence of structural heart disease (i.e. left ventricular hypertrophy or left atrial enlargement ) documented by the most recent echocardiogram, and/or cardiac MR within the last 12 months prior to enrolment. For patients with prior acute cardiac events or procedures that may reduce LVEF, e.g. as defined in exclusion criterion 6, qualifying cardiac imaging assessment at least 12 weeks following the procedure/event is required.
  5. Elevated NT-pro BNP levels.
  6. Both ambulatory and hospitalised patients may be enrolled and randomised. Patients currently hospitalised for HF, must be off intravenous HF medications for at least 24 before randomisation.

Further details regarding inclusion criteria 4-6 may apply.

Exclusion criteria

Exclusion Criteria:

  1. Receiving therapy with an SGLT2 inhibitor within 4 weeks prior to randomisation or previous intolerance to an SGLT2 inhibitor.
  2. Type 1 diabetes mellitus (T1D).
  3. \<25 mL/min/1.73 m2 (CKD-EPI formula) at Visit 1.
  4. Systolic blood pressure (BP) \<95 mmHg on 2 consecutive measurements at 5-minute intervals, at Visit 1 or at Visit 2.
  5. Systolic BP≥160 mmHg if not on treatment with ≥3 blood pressure lowering medications or ≥180 mmHg irrespective of treatments, on 2 consecutive measurements at 5-minute intervals, at Visit 1 or at Visit 2.
  6. MI, unstable angina, coronary revascularization (percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)), ablation of atrial flutter/fibrillation, valve repair/replacement within 12 weeks prior to enrolment. Before enrolment, these patients must have their qualifying echocardiography and/or cardiac MRI examination at least 12 weeks after the event.
  7. Planned coronary revascularization, ablation of atrial flutter/fibrillation and valve repair/replacement.
  8. Stroke or (TIA) within 12 weeks prior to enrolment.
  9. Probable alternative or concomitant diagnoses which in the opinion of the investigator could account for the patient's HF symptoms and signs (e.g. anaemia, hypothyroidism).
  10. >50 kg/m2.

Further exclusion criteria may apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
6,263 participants (actual)

Study arms

  • Experimental
    Dapagliflozin

    Patients will be randomized 1:1 to either dapagliflozin or placebo.

    Drug: Dapagliflozin

  • Placebo comparator
    Placebo

    Placebo matching dapagliflozin.

    Drug: Placebo

Interventions

  • 10 mg tablets given once daily, per oral use.

    Also known as: Forxiga TM, Farxiga TM

  • DrugPlacebo

    Placebo matching dapagliflozin 10 mg

06

What researchers measure

Primary outcomes

  1. Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.

    Dual primary efficacy Primary endpoint analysed in all patients randomised (Full analysis set). The analysis was assessed on Full Analysis Set, including events occurring on or prior to Primary Analysis Censoring Date.

    Time frame: Up to 42.1 months

  2. Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure for LVEF <60% Subpopulation

    Dual primary efficacy Primary endpoint analysed in all patients randomised with LVEF \< 60% at baseline. The analysis was assessed on Full Analysis Set, including events occurring on or prior to Primary Analysis Censoring Date.

    Time frame: Up to 42.1 months

Secondary outcomes

  1. Events Included in the Composite Endpoint of CV Death or Recurrent Heart Failure Event (Hospitalization Due to Heart Failure or Urgent Heart Failure Visit)

    Secondary efficacy Total number of heart failure events (first and recurrent) and cardiovascular death, analysed in all randomized patients. The analysis was assessed on Full Analysis Set, including events occurring on or prior to Primary Analysis Censoring Date.

    Time frame: Up to 42.1 months

  2. Events Included in the Composite Endpoint of CV Death or Recurrent Heart Failure Event (Hospitalization Due to Heart Failure or Urgent Heart Failure Visit) for LVEF <60% Subpopulation

    Secondary efficacy Total number of heart failure events (first and recurrent) and cardiovascular death, analysed in all randomized patients with LVEF \< 60% at baseline The analysis was assessed on Full Analysis Set, including events occurring on or prior to Primary Analysis Censoring Date.

    Time frame: Up to 42.1 months

  3. Change From Baseline in the KCCQ Total Symptom Score at 8 Months

    KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. The KCCQ Total Symptom Score incorporates the symptom domains into a single score. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

    Time frame: Baseline and 8 months or death before 8 months

  4. Subjects Included in the Endpoint of Cardiovascular Death

    Secondary efficacy The analysis was assessed on Full Analysis Set, including deaths occurring on or prior to Primary Analysis Censoring Date.

    Time frame: Up to 42.1 months

  5. Subjects Included in the Endpoint of All-cause Mortality

    Secondary efficacy The analysis was assessed on Full Analysis Set, including deaths occurring on or prior to Primary Analysis Censoring Date.

    Time frame: Up to 42.1 months

07

Results

Posted Jul 11, 2023

Participant flow

Participant flow — Overall Study
MilestoneDapa 10 mgPlacebo
Started31313132
Completed31213121
Not completed1011
Withdrew: Lost to follow-up21
Withdrew: Withdrawal by subject810

Outcome measures

PrimarySubjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.

Dual primary efficacy Primary endpoint analysed in all patients randomised (Full analysis set). The analysis was assessed on Full Analysis Set, including events occurring on or prior to Primary Analysis Censoring Date.

Time frame:
Up to 42.1 months
Reported as:
Count of participants · Participants
Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.
ParticipantsDapa 10 mgPlacebo
Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.512610
Statistical analysis
  • Dapa 10 mg vs Placebo · Regression, Cox · p = 0.0008 · Hazard ratio (hr): 0.82 · 95% CI 0.73 to 0.92Stratified by Type 2 Diabetes status at randomization.
PrimarySubjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure for LVEF <60% Subpopulation

Dual primary efficacy Primary endpoint analysed in all patients randomised with LVEF \< 60% at baseline. The analysis was assessed on Full Analysis Set, including events occurring on or prior to Primary Analysis Censoring Date.

Time frame:
Up to 42.1 months
Reported as:
Count of participants · Participants
Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure for LVEF <60% Subpopulation
ParticipantsDapa 10 mgPlacebo
Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure for LVEF <60% Subpopulation381440
Statistical analysis
  • Dapa 10 mg vs Placebo · Regression, Cox · p = 0.0085 · Hazard ratio (hr): 0.83 · 95% CI 0.73 to 0.95Stratified by Type 2 Diabetes status at randomization.
SecondaryEvents Included in the Composite Endpoint of CV Death or Recurrent Heart Failure Event (Hospitalization Due to Heart Failure or Urgent Heart Failure Visit)

Secondary efficacy Total number of heart failure events (first and recurrent) and cardiovascular death, analysed in all randomized patients. The analysis was assessed on Full Analysis Set, including events occurring on or prior to Primary Analysis Censoring Date.

Time frame:
Up to 42.1 months
Reported as:
Number · Number of events
Events Included in the Composite Endpoint of CV Death or Recurrent Heart Failure Event (Hospitalization Due to Heart Failure or Urgent Heart Failure Visit)
Number of eventsDapa 10 mgPlacebo
Events Included in the Composite Endpoint of CV Death or Recurrent Heart Failure Event (Hospitalization Due to Heart Failure or Urgent Heart Failure Visit)8151057
Statistical analysis
  • Dapa 10 mg vs Placebo · LWYY proportional rates model · p = 0.0003 · Rate ratio (rr): 0.77 · 95% CI 0.67 to 0.89Stratified by Type 2 Diabetes status at randomization
SecondaryEvents Included in the Composite Endpoint of CV Death or Recurrent Heart Failure Event (Hospitalization Due to Heart Failure or Urgent Heart Failure Visit) for LVEF <60% Subpopulation

Secondary efficacy Total number of heart failure events (first and recurrent) and cardiovascular death, analysed in all randomized patients with LVEF \< 60% at baseline The analysis was assessed on Full Analysis Set, including events occurring on or prior to Primary Analysis Censoring Date.

Time frame:
Up to 42.1 months
Reported as:
Number · Number of events
Events Included in the Composite Endpoint of CV Death or Recurrent Heart Failure Event (Hospitalization Due to Heart Failure or Urgent Heart Failure Visit) for LVEF <60% Subpopulation
Number of eventsDapa 10 mgPlacebo
Events Included in the Composite Endpoint of CV Death or Recurrent Heart Failure Event (Hospitalization Due to Heart Failure or Urgent Heart Failure Visit) for LVEF <60% Subpopulation605782
Statistical analysis
  • Dapa 10 mg vs Placebo · LWYY proportional rates model · p = 0.0017 · Rate ratio (rr): 0.77 · 95% CI 0.65 to 0.90Stratified by Type 2 Diabetes status at randomization
SecondaryChange From Baseline in the KCCQ Total Symptom Score at 8 Months

KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. The KCCQ Total Symptom Score incorporates the symptom domains into a single score. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

Time frame:
Baseline and 8 months or death before 8 months
Reported as:
Mean · Scores on a scale
Change From Baseline in the KCCQ Total Symptom Score at 8 Months
Scores on a scaleDapa 10 mgPlacebo
Change From Baseline in the KCCQ Total Symptom Score at 8 Months8.3 ± 20.35.2 ± 21.1
Statistical analysis
  • Dapa 10 mg vs Placebo · Win Ratio · p = 0.0086 (The p-value is obtained from a rank ANCOVA adjusted for baseline KCCQ score, stratified by T2DM status at randomisation.) · Rate ratio (rr): 1.11 · 95% CI 1.03 to 1.21The composite of change from baseline in KCCQ Total Symptom Score at 8 months, or death before 8 months.
SecondarySubjects Included in the Endpoint of Cardiovascular Death

Secondary efficacy The analysis was assessed on Full Analysis Set, including deaths occurring on or prior to Primary Analysis Censoring Date.

Time frame:
Up to 42.1 months
Reported as:
Count of participants · Participants
Subjects Included in the Endpoint of Cardiovascular Death
ParticipantsDapa 10 mgPlacebo
Subjects Included in the Endpoint of Cardiovascular Death231261
Statistical analysis
  • Dapa 10 mg vs Placebo · Regression, Cox · p = 0.1678 · Hazard ratio (hr): 0.88 · 95% CI 0.74 to 1.05Stratified by Type 2 Diabetes status at randomization.
SecondarySubjects Included in the Endpoint of All-cause Mortality

Secondary efficacy The analysis was assessed on Full Analysis Set, including deaths occurring on or prior to Primary Analysis Censoring Date.

Time frame:
Up to 42.1 months
Reported as:
Count of participants · Participants
Subjects Included in the Endpoint of All-cause Mortality
ParticipantsDapa 10 mgPlacebo
Subjects Included in the Endpoint of All-cause Mortality497526
Statistical analysis
  • Dapa 10 mg vs Placebo · Regression, Cox · p = 0.3425 · Hazard ratio (hr): 0.94 · 95% CI 0.83 to 1.07Stratified by Type 2 Diabetes status at randomization.

Adverse events

Collected over [All-cause mortality]: From randomization until end of study, up to 42.2 months. [Serious AE and other AE] From first dose until end of study, up to 42.2 months.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dapa 10 mg510/3,131 (16.3%)1,454/3,126 (46.5%)464/3,126 (14.8%)
Placebo533/3,132 (17%)1,508/3,127 (48.2%)485/3,127 (15.5%)
Most frequent serious events
Showing 10 of 903
Most frequent serious events
EventDapa 10 mgPlacebo
Cardiac failureCardiac disorders308/3126377/3127
Covid-19Infections and infestations183/3126144/3127
PneumoniaInfections and infestations113/3126106/3127
Covid-19 pneumoniaInfections and infestations86/312689/3127
Cardiac failure congestiveCardiac disorders63/312682/3127
Ischaemic strokeNervous system disorders70/312665/3127
Atrial fibrillationCardiac disorders69/312657/3127
Acute myocardial infarctionCardiac disorders63/312663/3127
Cardiac failure acuteCardiac disorders57/312663/3127
Acute kidney injuryRenal and urinary disorders54/312663/3127
Most frequent other events
Most frequent other events
EventDapa 10 mgPlacebo
Cardiac failureCardiac disorders179/3126214/3127
Urinary tract infectionInfections and infestations113/3126112/3127
HypertensionVascular disorders84/3126102/3127
Atrial fibrillationCardiac disorders86/312661/3127
HypotensionVascular disorders69/312661/3127

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Dapa 10 mgPlaceboTotal
Mean71.8 ± 9.671.5 ± 9.571.7 ± 9.6
Age, Customized
Age, Customized(Participants)Dapa 10 mgPlaceboTotal
<= 508574159
> 50304630586104
Age, Customized
Age, Customized(Participants)Dapa 10 mgPlaceboTotal
<= 657437611504
> 65238823714759
Age, Customized
Age, Customized(Participants)Dapa 10 mgPlaceboTotal
<= 657437611504
>65 - 75118412282412
> 75120411432347
Sex: Female, Male
Sex: Female, Male(Participants)Dapa 10 mgPlaceboTotal
Female136413832747
Male176717493516
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dapa 10 mgPlaceboTotal
Hispanic or Latino6325981230
Not Hispanic or Latino249925345033
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dapa 10 mgPlaceboTotal
White221422254439
Black or African American8178159
Asian6306441274
Native Hawaiian or other Pacific Islander000
American Indian or Alaska Native9396189
Other11389202
Prior HF Hospitalization
Prior HF Hospitalization(Participants)Dapa 10 mgPlaceboTotal
Yes127012692539

3 further baseline measures are reported on the registry.

08

Study locations

348 sites
  • Research Site
    Fairhope, Alabama 36532, United States
  • Research Site
    Mobile, Alabama 36608, United States
  • Research Site
    Sheffield, Alabama 35660, United States
  • Research Site
    Tucson, Arizona 85724, United States
  • Research Site
    Little Rock, Arkansas 72204, United States
  • Research Site
    Beverly Hills, California 90211, United States
  • Research Site
    Loma Linda, California 92357, United States
  • Research Site
    Los Angeles, California 90073, United States
  • Research Site
    Stamford, Connecticut 06905, United States
  • Research Site
    Clearwater, Florida 33756, United States
  • Research Site
    Miami, Florida 33155, United States
  • Research Site
    Naples, Florida 34102, United States
  • Research Site
    Ocala, Florida 34471, United States
  • Research Site
    Ormond Beach, Florida 32174, United States
  • Research Site
    Port Charlotte, Florida 33952, United States
  • Research Site
    Saint Augustine, Florida 32086, United States
  • Research Site
    Atlanta, Georgia 30303, United States
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Gurnee, Illinois 60031, United States
  • Research Site
    Anderson, Indiana 46011, United States
  • Research Site
    Munster, Indiana 46321, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Hammond, Louisiana 70403, United States
  • Research Site
    Houma, Louisiana 70360, United States
  • Research Site
    Monroe, Louisiana 71201, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Bay City, Michigan 48708, United States
  • Research Site
    Flint, Michigan 48504, United States
  • Research Site
    Flint, Michigan 48532, United States
  • Research Site
    Minneapolis, Minnesota 55417, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Saint Paul, Minnesota 55102, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    Kansas City, Missouri 64128, United States
  • Research Site
    Saint Louis, Missouri 63136, United States
  • Research Site
    Great Falls, Montana 59405, United States
  • Research Site
    Las Vegas, Nevada 89106, United States
  • Research Site
    Lebanon, New Hampshire 03756, United States
  • Research Site
    Bridgewater, New Jersey 08807, United States
  • Research Site
    Buffalo, New York 14215, United States
  • Research Site
    New York, New York 10001, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Charlotte, North Carolina 28277, United States
  • Research Site
    Greensboro, North Carolina 27405, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research Site
    Oklahoma City, Oklahoma 73134, United States
  • Research Site
    Altoona, Pennsylvania 16601, United States
  • Research Site
    Doylestown, Pennsylvania 18901, United States
  • Research Site
    Providence, Rhode Island 02908, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Rapid City, South Dakota 57701, United States
  • Research Site
    Jackson, Tennessee 38301, United States
  • Research Site
    Nashville, Tennessee 37212, United States
  • Research Site
    Tullahoma, Tennessee 37388, United States
  • Research Site
    Beaumont, Texas 77701, United States
  • Research Site
    Humble, Texas 77338, United States
  • Research Site
    Sherman, Texas 75092, United States
  • Research Site
    Burlington, Vermont 05401, United States
  • Research Site
    Falls Church, Virginia 22042, United States
  • Research Site
    Leesburg, Virginia 20176, United States
  • Research Site
    Morgantown, West Virginia 26506, United States
  • Research Site
    Madison, Wisconsin 53705, United States
  • Research Site
    Milwaukee, Wisconsin 53295, United States
  • Research Site
    Buenos Aires, C1426ABP, Argentina
  • Research Site
    Caba, 1426, Argentina
  • Research Site
    Caba, C1119ACN, Argentina
  • Research Site
    Caba, C1120AAC, Argentina
  • Research Site
    Caba, C1425AGC, Argentina
  • Research Site
    Catamarca, K4700, Argentina
  • Research Site
    Ciudad Autonoma de Buenos Aire, C1407GTN, Argentina
  • Research Site
    Cordoba, 5003, Argentina
  • Research Site
    Cordoba, X5000AAW, Argentina
  • Research Site
    Cordoba, X5003DCP, Argentina
  • Research Site
    Cordoba, X5006CBI, Argentina
  • Research Site
    Corrientes, W3400AMZ, Argentina
  • Research Site
    Córdoba, X5004BAL, Argentina
  • Research Site
    Mar del Plata, 7600, Argentina
  • Research Site
    Ramos Mejía, B1704ETD, Argentina
  • Research Site
    Rosario, 2000, Argentina
  • Research Site
    San Miguel de Tucuman, 4000, Argentina
  • Research Site
    San Nicolás, B2900DMH, Argentina
  • Research Site
    Santa Fe, S3000FWO, Argentina
  • Research Site
    Aalst, 9300, Belgium
  • Research Site
    Brasschaat, 2930, Belgium
  • Research Site
    Bruxelles, 1200, Belgium
  • Research Site
    Huy, 4500, Belgium
  • Research Site
    Kortrijk, 8500, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Belo Horizonte, 30150-240, Brazil
  • Research Site
    Belo Horizonte, 30210-090, Brazil
  • Research Site
    Blumenau, 89020-430, Brazil
  • Research Site
    Campina Grande do Sul, 83430000, Brazil
  • Research Site
    Campinas, 13010-001, Brazil
  • Research Site
    Campinas, 13060-080, Brazil
  • Research Site
    Curitiba, 80230-130, Brazil
  • Research Site
    Porto Alegre, 90020090, Brazil
  • Research Site
    Porto Alegre, 90035-903, Brazil

Showing the first 100 of 348 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Inzucchi SE, Claggett BL, Vaduganathan M, Desai AS, Jhund PS, de Boer RA, Hernandez AF, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Verma S, Han Y, Kerr Saraiva JF, Bengtsson O, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2022 Dec;10(12):869-881. doi: 10.1016/S2213-8587(22)00308-4. Epub 2022 Nov 10. PubMed 36372069 ↗
  • Mc Causland FR, Claggett BL, Vaduganathan M, Desai AS, Jhund P, de Boer RA, Docherty K, Fang J, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Saraiva JFK, McGrath MM, Shah SJ, Verma S, Langkilde AM, Petersson M, McMurray JJV, Solomon SD. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiol. 2023 Jan 1;8(1):56-65. doi: 10.1001/jamacardio.2022.4210. PubMed 36326604 ↗
  • Vaduganathan M, Claggett BL, Jhund P, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Hegde SM, Lindholm D, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiol. 2022 Dec 1;7(12):1259-1263. doi: 10.1001/jamacardio.2022.3750. PubMed 36190011 ↗
  • Desai AS, Jhund PS, Claggett BL, Vaduganathan M, Miao ZM, Kondo T, Barkoudah E, Brahimi A, Connolly E, Finn P, Lang NN, Mc Causland FR, McGrath M, Petrie MC, McMurray JJV, Solomon SD. Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER. JAMA Cardiol. 2022 Dec 1;7(12):1227-1234. doi: 10.1001/jamacardio.2022.3736. PubMed 36189985 ↗
  • Myhre PL, Vaduganathan M, Claggett BL, Miao ZM, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Lindholm D, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Fail. 2022 Dec;10(12):902-913. doi: 10.1016/j.jchf.2022.08.007. Epub 2022 Aug 27. PubMed 36114137 ↗
  • Peters AE, Ogunniyi MO, Hegde SM, Bianco C, Ghafghazi S, Hernandez AF, DeVore AD. A multicenter program for electronic health record screening for patients with heart failure with preserved ejection fraction: Lessons from the DELIVER-EHR initiative. Contemp Clin Trials. 2022 Oct;121:106924. doi: 10.1016/j.cct.2022.106924. Epub 2022 Sep 12. PubMed 36100197 ↗
  • Cunningham JW, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, McGrath MM, O'Meara E, Wilderang U, Lindholm D, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. J Am Coll Cardiol. 2022 Oct 4;80(14):1302-1310. doi: 10.1016/j.jacc.2022.07.021. Epub 2022 Aug 27. PubMed 36041912 ↗
  • Vaduganathan M, Claggett BL, Jhund P, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Lindholm D, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure. J Am Coll Cardiol. 2022 Nov 8;80(19):1775-1784. doi: 10.1016/j.jacc.2022.08.745. Epub 2022 Aug 27. PubMed 36041669 ↗
  • Butt JH, Kondo T, Jhund PS, Comin-Colet J, de Boer RA, Desai AS, Hernandez AF, Inzucchi SE, Janssens SP, Kosiborod MN, Lam CSP, Langkilde AM, Lindholm D, Martinez F, Petersson M, Shah SJ, Thierer J, Vaduganathan M, Verma S, Wilderang U, Claggett BC, Solomon SD, McMurray JJV. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction. J Am Coll Cardiol. 2022 Nov 1;80(18):1705-1717. doi: 10.1016/j.jacc.2022.08.718. Epub 2022 Aug 27. PubMed 36041668 ↗
  • Peikert A, Martinez FA, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Shah SJ, Katova T, Merkely B, Vardeny O, Wilderang U, Lindholm D, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial. Circ Heart Fail. 2022 Oct;15(10):e010080. doi: 10.1161/CIRCHEARTFAILURE.122.010080. Epub 2022 Aug 27. PubMed 36029467 ↗
  • Butt JH, Jhund PS, Belohlavek J, de Boer RA, Chiang CE, Desai AS, Drozdz J, Hernandez AF, Inzucchi SE, Katova T, Kitakaze M, Kosiborod MN, Lam CSP, Maria Langkilde A, Lindholm D, Bachus E, Martinez F, Merkely B, Petersson M, Saraiva JFK, Shah SJ, Vaduganathan M, Vardeny O, Wilderang U, Claggett BL, Solomon SD, McMurray JJV. Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation. 2022 Oct 18;146(16):1210-1224. doi: 10.1161/CIRCULATIONAHA.122.061754. Epub 2022 Aug 27. PubMed 36029465 ↗
  • Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderang U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM; DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022 Sep 22;387(12):1089-1098. doi: 10.1056/NEJMoa2206286. Epub 2022 Aug 27. PubMed 36027570 ↗
  • Solomon SD, Vaduganathan M, Claggett BL, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Belohlavek J, Chiang CE, Willem Borleffs CJ, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Kerr Saraiva JF, Tereschenko SN, Thierer J, Vardeny O, Verma S, Vinh PN, Wilderang U, Zaozerska N, Lindholm D, Petersson M, McMurray JJV. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial. JACC Heart Fail. 2022 Mar;10(3):184-197. doi: 10.1016/j.jchf.2021.11.006. PubMed 35241246 ↗
  • Kanie T, Mizuno A, Takaoka Y, Suzuki T, Yoneoka D, Nishikawa Y, Tam WWS, Morze J, Rynkiewicz A, Xin Y, Wu O, Providencia R, Kwong JS. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev. 2021 Oct 25;10(10):CD013650. doi: 10.1002/14651858.CD013650.pub2. PubMed 34693515 ↗
  • Nassif ME, Kosiborod M. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure. Diabetes Obes Metab. 2019 Apr;21 Suppl 2:19-23. doi: 10.1111/dom.13678. PubMed 31081589 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Mar 2022, 43 months.

Results were first posted in Jul 2023, 1 year 3 months after primary completion.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 43 months is above that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2018
First posted
Aug 7, 2018
StartActual
Aug 27, 2018
Primary completionActual
Mar 27, 2022
CompletionActual
Mar 27, 2022
Results first posted
Jul 11, 2023
Last update
Jul 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03619213
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 7, 2018
Start date
Aug 27, 2018
Primary completion
Mar 27, 2022
Completion
Mar 27, 2022
Results posted
Jul 11, 2023
Last update
Jul 11, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion